Continuing Education Course

Learn more about the webinar series on the Injury Prevention Center’s website Benzodiazepines: Prescribing, Tapering, and Polysubstance Use Date: July 23, 2026 Time: 12:00pm-1:30pm ET Moderator: Michael Smith, PharmD, BCPS Speakers: Amy Vandenberg, PharmD, Alek Adkins, MD Target Audience: Physicians and Medical Students, although the session is open to all At the conclusion of this activity, participants ...

This session is designed to clarify the role of benzodiazepines in modern clinical practice. Participants will review core pharmacology and appropriate indications, examine common misconceptions, and assess key risks such as tolerance, dependence, withdrawal, and drug–drug interactions. The session will also emphasize safety-focused strategies for prescribing, monitoring, and tapering benzodiazepines to support informed, responsible, and ...

This session will explore the health risks associated with incarceration, with a focus on the transition from carceral to community settings among individuals with a history of opioid use disorder. We examine common barriers to care faced after release and highlight strategies to strengthen clinical engagement. Participants will gain practical skills to support more effective, ...

Alcohol use disorder (AUD) is common, underdiagnosed, and a major contributor to rising liver-related morbidity and mortality. This session reviews evidence-based strategies for screening, diagnosing, and treating AUD, including behavioral and medication options appropriate for patients with liver disease. Participants will gain practical tools to improve identification and management of AUD in routine clinical care. ...

Substance use during pregnancy continues to evolve, with new patterns, substances, and care challenges. This session will provide an overview of recent trends in substance use among pregnant and postpartum populations, discuss associated maternal and neonatal outcomes, and highlight evidence-based strategies for management. Participants will gain insight into how evolving drug trends intersect with stigma, ...

During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death, and providers that hold a DEA license with Schedule III Authority ...

U-M Addiction Treatment Services (UMATS) Lunch & Learn: Integrated Care for People with Liver Disease and Alcohol Use Disorders Ponni Perumalswami, MD, MSCR, is a Clinical Professor of Internal Medicine (Gastroenterology & Hepatology) and Clinical Associate Professor of Psychiatry at the University of Michigan Medical School. In this session, she will review alcohol-related liver injury, ...